Editas MedicineEDIT -0.18%51 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates EDIT with a GF Score™ of 51/100 and a GF Value™ of $1.92 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 377 Biotechnology companies, Editas Medicine ranks worse than 265251.72% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Editas Medicine's
Operating Income
for the
three
months ended in Mar. 2026 was $-25.00 Mil. Editas Medicine's Interest Expense for the
three
months ended in Mar. 2026 was $-1.07 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Editas Medicine's Interest Coverage or its related term are showing as below:
EDIT's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07 * Ranked among companies with meaningful Interest Coverage only.
Editas Medicine (NAS:EDIT) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Editas Medicine Interest Coverage Related Terms
Editas Medicine Interest Coverage Historical Data
* Premium members only.
The historical data trend for Editas Medicine's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
EDIT vs PRTA, XOMA, FDMT: Interest Coverage Comparison
For the Biotechnology subindustry, Editas Medicine's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Editas Medicine's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Editas Medicine did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Editas Medicine (EDIT) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Editas Medicine and its competitors. According to the industry distribution chart, Editas Medicine ranks #999999 out of 377 companies in the Biotechnology industry.
Is Editas Medicine's Interest Coverage too high?
Editas Medicine's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Editas Medicine ranks #999999 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Editas Medicine has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Interest Coverage compare to PRTA and XOMA?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #999999 out of 377 companies for Interest Coverage. This places Editas Medicine in the lower half of its industry. The industry median Interest Coverage is 106.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Editas Medicine and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Editas Medicine's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.92, compared to a current price of $2.80 — trading 45.6% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Editas Medicine's overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Editas Medicine (EDIT), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (EDIT) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $2.80 is trading 45.6% above its estimated GF Value™ of $1.92.
GuruFocus considers Editas Medicine to be Significantly Overvalued.
Key valuation signals for EDIT:
Interest Coverage: 0 (At Loss)
GF Value™: $1.92 vs. price of $2.80 (45.6% above fair value)
No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
51GF Score
Get the complete analysis for EDIT
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDIT has been successfully added to your 
